Table 2.
Criteria for identifying adult patients at risk for RFS
NICE [48] | ASPEN 2020 [33] | Friedli 2018 [21] | |||||
---|---|---|---|---|---|---|---|
High risk in the presence of | Moderate risk: 2 risk criteria needed | Significant risk: 1 risk criteria needed | Low risk: 1 minor risk factor | High risk: 1 major or 2 minor risk factors | Very high risk | ||
One or more of the following: | Two or more of the following: | Minor risk factors | Major risk factors | ||||
BMI | < 16 kg/m2 | < 18.5 kg/m2 | 16–18.5 kg/m2 | < 16 kg/m2 | < 18.5 kg/m2 | < 16 kg/m2 | < 14 kg/m2 |
Weight loss | > 15% within the last 3–6 months | > 10% within the last 3–6 months | 5% in 1 month | 7.5% in 3 months or > 10% in 6 months | > 10% within the last 3–6 months | > 15% within the last 3–6 months | > 20% |
Caloric intake | Little or no nutritional intake > 10 days | Little or no nutritional intake > 5 days |
None or negligible oral intake for 5–6 days OR < 75% of estimated energy requirement for > 7 days during an acute illness or injury OR < 75% of estimated energy requirement for > 1 month |
None or negligible oral intake for > 7 days OR < 50% of estimated energy requirement for > 5 days during an acute illness or injury OR < 50% of estimated energy requirement for > 1 month |
Little or no nutritional intake > 5 days | Little or no nutritional intake > 10 days | Starvation > 15 days |
Prefeeding potassium, phosphate, or magnesium serum concentrations | Low levels | Minimally low levels or normal current levels and recent low levels necessitating minimal or single‐dose supplementation | Moderately/significantly low levels or minimally low or normal levels and recent low levels necessitating significant or multiple‐dose supplementation | Low levels | |||
Loss of subcutaneous fat | Evidence of moderate loss | Evidence of severe loss | |||||
Loss of muscle mass | Evidence of mild or moderate loss | Evidence of severe loss | |||||
Higher‐risk comorbidities* | A history of alcohol abuse or drugs including insulin, chemotherapy, antacids, or diuretics | Moderate disease | Severe disease | A history of alcohol abuse or drugs including insulin, chemotherapy, antacids, or diuretics |
BMI body mass index
*Acquired immunodeficiency syndrome; Advanced neurologic impairment or general inability to communicate needs; Cancer; Chronic alcohol or drug use disorder; Dysphagia and esophageal dysmotility; Eating disorders; Food insecurity and homelessness; Failure to thrive, including physical and sexual abuse and victims of neglect; Hyperemesis gravidarum or protracted vomiting; Major stressors or surgery without nutrition for prolonged periods of time; Malabsorptive states (e.g., short‐bowel syndrome, Crohn’s disease, cystic fibrosis, pyloric stenosis, maldigestion, pancreatic insufficiency); Postbariatric surgery; Postoperative patients with complications; Prolonged fasting; Protein malnourishment; Refugees